Eurofins Viracor BioPharma is excited to share that we now offer nanoString technology* with the addition of our new nCounter® Pro Analysis System.
The drug development process can be complicated, consisting of many highly involved stages. To avoid costly missteps, it is critical to have well-validated biomarkers that play a critical role in every stage of the drug development process. NanoString’s platform generates robust biomarker data from limited and challenging sample types and can be utilized for sample analysis to advance drug development programs. Whether your research requires bulk, single-cell or sub-cellular spatial analysis, this innovative technology can help accelerate your drug development studies.
The nCounter Pro is an advanced, high-performance digital gene expression system that provides highly reproducible gene expression data for up to 800 genes at a time. It uses direct detection technology along with minimal sample preparation and an automated workflow to provide rapid access to results and accelerate research programs. The system is a powerful and reliable tool for scalable gene expression analysis for a variety of applications
The PanCancer IO 360 Gene Expression Panel is a unique 770 gene expression panel that combines vital components involved in the complex interplay between the tumor, microenvironment, and immune response in cancer, allowing for a multifaceted characterization of disease biology and interrogation of mechanisms of immune evasion.
The nCounter PanCancer IO 360™ Panel is designed specifically for immuno-oncology and translational researchers who are studying the impact of immune evasion in the tumor microenvironment and developing potentially prognostic, predictive or mechanism of action signatures for immunotherapy.